Amarin Corp Plc (AMRN)

[couldbebetter]

Lovasa will eat both the lunch of both Vascepa and Generic Vascepa.
Without patients, doctors, and insurers understanding the real health
benefits of Vascepa they will gravitate to what they see as the least
costly option which is generic Lovasa. Sad that the FDA has no interest
in correcting this. I say sell us to BP and if that were Pfizer, they
might have the political clout with the FDA to get them to find a
resolution beneficial to Pfizer.